- Home
- CANF vs AYTU Comparison
CANF vs AYTU Comparison
Compare CANF & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- AYTU
- Stock Information
- Founded
- CANF 1994
- AYTU N/A
- Country
- CANF Israel
- AYTU United States
- Employees
- CANF N/A
- AYTU N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- AYTU Health Care
- Exchange
- CANF Nasdaq
- AYTU Nasdaq
- Market Cap
- CANF 9.4M
- AYTU 8.3M
- IPO Year
- CANF N/A
- AYTU N/A
- Fundamental
- Price
- CANF $1.81
- AYTU $1.35
- Analyst Decision
- CANF Strong Buy
- AYTU
- Analyst Count
- CANF 2
- AYTU 0
- Target Price
- CANF $14.00
- AYTU N/A
- AVG Volume (30 Days)
- CANF 122.9K
- AYTU 30.9K
- Earning Date
- CANF 03-04-2025
- AYTU 02-12-2025
- Dividend Yield
- CANF N/A
- AYTU N/A
- EPS Growth
- CANF N/A
- AYTU N/A
- EPS
- CANF N/A
- AYTU N/A
- Revenue
- CANF $667,000.00
- AYTU $77,232,000.00
- Revenue This Year
- CANF $409.56
- AYTU N/A
- Revenue Next Year
- CANF N/A
- AYTU N/A
- P/E Ratio
- CANF N/A
- AYTU N/A
- Revenue Growth
- CANF N/A
- AYTU N/A
- 52 Week Low
- CANF $1.29
- AYTU $1.30
- 52 Week High
- CANF $4.69
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- CANF 64.57
- AYTU 32.11
- Support Level
- CANF $1.45
- AYTU $1.35
- Resistance Level
- CANF $1.50
- AYTU $1.44
- Average True Range (ATR)
- CANF 0.12
- AYTU 0.10
- MACD
- CANF 0.05
- AYTU -0.02
- Stochastic Oscillator
- CANF 66.67
- AYTU 2.63
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.